According to the TIMER 2.0 database, the differential expression of ASPHD1 in various cancers was showing in Fig. 1A. The ASPHD1 expression levels were significantly upregulated in 15 kinds of cancers, including gastrointestinal cancer, hepatobiliary carcinoma, urological tumor, lung cancer, and breast invasive carcinoma, but decreased in glioblastoma multiforme compared with normal tissues. Here, ASPHD1 is linked to invasive breast carcinoma.